Trial Profile
Open-label Multicenter, Phase I/II Study Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal Neovascularisation (CNV) Secondary to Age-related Macular Degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Jun 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Therapeutic Use
- Acronyms EXTEND-I
- Sponsors Novartis
- 15 Aug 2014 New trial record
- 17 Nov 2006